Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Asphelia Pharmaceuticals Inc.
Coronado gets $25.8 million boost to pursue parasite-based autoimmune disease therapy
Coronado Biosciences is out to help prove that mom is not always right when it comes to cleanliness, and investors, led by National Securities, were willing to give the New York-based biotech $25.8 million to back that up.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice